ArticleBMC cancer2025
Deep learning radiomics for the prediction of epidermal growth factor receptor mutation status based on MRI in brain metastasis from lung adenocarcinoma patients.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- DriverNet: A Clinical and MRI-Based Framework for Noninvasive Pre-Treatment Molecular Triage in NSCLC Brain Metastases.Diagnostics (Basel, Switzerland) · 2026Article
- Systematic review and meta-analysis of AI in lung cancer metastasis imaging for diagnosis and prognosis.NPJ digital medicine · 2026Article
- Magnetic resonance imaging characteristics of brain metastases from lung cancer.Quantitative imaging in medicine and surgery · 2026Article
- Artificial Intelligence Tools in Precision Lung Cancer Care: From Early Detection to Clinical Decision Support.Cancers · 2026Review
- Post-treatment triglyceride-glucose index as survival protective factors in patients with esophageal squamous cell carcinoma.World journal of clinical oncology · 2026Article
- Intranodular and perinodular radiomics features based on non-contrast CT to distinguish pulmonary cryptococcosis from lung adenocarcinoma: a two-center study.Frontiers in oncology · 2026Article
- Prediction of EGFR mutation status in non-small cell lung cancer based on multiparametric MRI radiomics.BMC medical imaging · 2025Article
- Radiogenomics: transforming lung cancer care through non-invasive imaging and genomic integration.Medical oncology (Northwood, London, England) · 2025Review
- Deep learning enhances precision diagnosis and treatment of non-small cell lung cancer: future prospects.Translational lung cancer research · 2025Review
- The Impact of Artificial Intelligence on Lung Cancer Diagnosis and Personalized Treatment.International journal of molecular sciences · 2025Review
- Deep learning and inflammatory markers predict early response to immunotherapy in unresectable NSCLC: A multicenter study.Biomolecules & biomedicine · 2025Article
- Association between keratin 8 expression and immune-related pneumonitis: a case-control study in lung adenocarcinoma patients.Frontiers in immunology · 2025Article
- Development and validation of a deep learning model using MR imaging for predicting brain metastases: an accuracy-focused study.Frontiers in oncology · 2025Article
- Applications and challenges of multi-omics approaches in lung cancer research and precision treatment.Frontiers in genetics · 2025Review
- Pyroptosis-Mediator GSDMD in Plasma: A Potent Biomarker Lung Cancer Diagnosis and Prognosis Assessment.International journal of general medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundEarly and accurate identification of epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) patients with brain metastases is critical for guiding targeted therapy. This study aimed to develop a deep learning radiomics model utilizing multi-sequence magnetic resonance imaging (MRI) to differentiate between EGFR mutant type (MT) and wild type (WT).
methodsIn this retrospective study, 288 NSCLC patients with confirmed brain metastases were enrolled, including 106 with EGFR MT and 182 with EGFR WT. All patients were randomly divided into a training dataset (75%) and a validation dataset (25%). Radiomics and deep learning features were extracted from the brain metastatic lesions using contrast-enhanced T1-weighted (T1CE) and T2-weighted (T2W) MRI images. Features extraction and selection were performed using the least absolute shrinkage and selection operator (LASSO) and ResNet34. The predictive performance of the signatures for EGFR mutation status was assessed using receiver operating characteristic (ROC) curves and area under the curve (AUC) analyses.
resultsNo significant differences were found between the training and validation datasets. A four-feature radiomics signature (RS) demonstrated excellent predictive accuracy for EGFR MT, with α-binormal-based and empirical AUCs of 0.931 (95% CI: 0.880-0.940) and 0.926 (95% CI: 0.877-0.933), respectively. Incorporating deep learning signature (DLS) further enhanced the model's performance, achieving α-binormal-based and empirical AUCs of 0.943 (95% CI: 0.921-0.965) and 0.938 (95% CI: 0.914-0.962) in the training dataset. These findings were confirmed in the validation dataset, with AUCs of 0.936 (95% CI: 0.917-0.955) and 0.921 (95% CI: 0.901-0.941), demonstrating robust and consistent predictive performance.
conclusionsThe multi-sequence MRI-based deep learning radiomics model exhibited high efficacy in predicting EGFR mutation status in NSCLC patients with brain metastases. This approach, which integrates advanced radiological features with deep learning techniques, offers a non-invasive and accurate method for determining EGFR mutation status, potentially guiding personalized treatment decisions in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.